Central catecholaminergjc neurons are involved in cardiovascular regulation. Neuropeptide Y (NPY) coexists with adrenaline and noradrenaline in the rat brain, and interactions among these substances have been studied. The purpose of this study was to investigate the possible role of NPY in central cardiovascular control. Male Sprague-Dawley rats were anesthetized with urethane, and blood pressure was monitored intra-arterially. Intramedullary mkroinjection (60 nl) of NPY (0, 46.5 fmol, 465 fmol, 1.5 pmol, and 4.65 pmol) was made into the nucleus tractus solitarii (NTS), into the area postrema, and into the Cl area in the rostroventrolateral medulla. Injection site was identified by L-glutamate administration and confirmed histologically. Unilateral injection of NPY into the NTS produced a prominent dose-related decrease in heart rate and systolic and diastolic blood pressure (-106±8 beats/min, -5 6 ± 2 mm Hg, and -3 3 ± 2 mm Hg, respectively after 4.65 pmol NPY, n=7, /><0.001). Maximal changes occurred at 30 seconds and recovered in 10 minutes for blood pressure and 20 minutes for heart rate. Injection into the area postrema produced an initial increase in heart rate and mean blood pressure (+23 ±2 beats/min and +18 ±2 mm Hg) followed by a prolonged decrease in heart rate and mean blood pressure (-14±4 beats/min and -15±2 mm Hg, respectively, n=7, /;<0.01). However, injection of NPY into the Cl area produced a dose-related increase in blood pressure and a decrease in heart rate (+17±1 mm Hg and -23±8 beats/min, n=6, /?<0.01). To test the specific effect of NPY, rabbit anti-NPY antiserum was used. Prior administration of the antiserum inhibited the effects of subsequent administration of NPY, whereas inactivated antiserum was not able to prevent these effects. These studies demonstrate that NPY has powerful cardiovascular effects in the NTS, area postrema, and Cl area of the medulla oblongata of the rat. This finding suggests that NPY may be important in cardiovascular regulation. (Circulation Research 1988;64:55-61) N europeptide Y (NPY), a 36-amino acid peptide 12 has been increasingly studied for its possible role as neuromodulator, both in the central nervous system and in the periphery. Recent evidence has suggested a role for NPY in the central control of blood pressure (BP) and heart rate (HR). For instance, this peptide coexists with adrenaline and noradrenaline in the catecholaminergic system of the rat brain.
N europeptide Y (NPY), a 36-amino acid peptide 12 has been increasingly studied for its possible role as neuromodulator, both in the central nervous system and in the periphery. Recent evidence has suggested a role for NPY in the central control of blood pressure (BP) and heart rate (HR). For instance, this peptide coexists with adrenaline and noradrenaline in the catecholaminergic system of the rat brain. 3 - 5 In addition, NPY and catecholamines are probably released by sympathetic activation. 6 -9 More importantly, immunohistochemical evidence demonstrated that NPY-perikarya and nerve terminals are located in relevant areas of central cardiovascular control such as the nucleus of the solitary tract (NTS) 10 and the Cl area in the brainstem. 11 More direct evidence for a role of NPY in central cardiovascular control came from pharmacological studies which indicated that NPY is able to affect hemodynamic parameters. Intracisternal (i.e.) administration of NPY in rats caused a marked depressor response, 12 whereas in the third ventricle, NPY caused an increase in both BP and HR. 13 Local administration of NPY in the NTS area has been reported to have biphasic effects with pressor to low doses and depressor to high doses. 14 However, specific receptor antagonists for NPY are not available, and the possibility of nonspecific effects of the exogenously administered peptide remains.
In the present study, we decided to investigate the cardiovascular effects of NPY in the area postrema (AP) and Cl area of the brainstem of urethane anesthetized rats and with the use of an NPY antiserum to evaluate the specificity of the NPY effects in the NTS. The results suggest that NPY has potent and specific cardiovascular activity in the brainstem with only depressor effects in the NTS.
Materials and Methods
Male Sprague-Dawley rats were obtained from Sasco Sprague-Dawley, St. Louis, Missouri. The animals were housed in an animal room with a light/ dark cycle of 12:12 and were fed rat chow and tap water ad libitum. Rats were 3-5 months old when used and weighed between 280 and 350 g.
Rats were anesthetized with urethane (1.0 g/kg i.p. and 300 mg/kg i.v., if necessary). A polyethylene cannula was placed in the femoral vein for administration of drugs, and BP was measured directly through a cannula placed into the femoral artery and connected to a pressure transducer (P23 ID, Gould, Cleveland, Ohio) and a polygraph (RS3800, Gould). Heart rate was monitored continuously by a tachograph preamplifier Gould) . After the trachea was cannulated, respiratory rate was counted through a thermistor probe (YS1 series, 1-8456-00, Cole-Palmer Instruments, Chicago, Illinois) implanted in the cannulated tracheal tube and connected to the polygraph.
The animals were then placed in a stereotaxic instrument (Kopf), with the head flexed downward at a 45° angle. The dorsal surface of the medulla was exposed by limited craniotomy, and the animals were rested for at least 1 hour before experiments. For microinjections into the brain nuclei, glass cannulae were prepared (0.031" o.d., 0.006" i.d., Richland Glass Co, Richland, New Jersey) with an external tip diameter of 40 fim. The cannula was connected to a Hamilton microsyringe through polyvinyl tubing. The cannulae were either filled with L-glutamate (2. During the experiment, the injection sites in the NTS and Cl area were confirmed by responsiveness to L-glutamate administration. An important and specific decrease in BP and HR (at least -35 mm Hg and -50 beats/min) has been demonstrated following microinjection of 2.3 nmol of L-glutamate in the NTS. 15 The response is restricted to the intermediate one third of the NTS, and administration of the same dose of L-glutamate in adjacent areas to the NTS failed to elicit the response. In the Cl area, L-glutamate increases both BP and HR. An immediate increase in mean BP of >40 mm Hg after microinjection of L-glutamate was taken as indicative that the injection site was on the Cl area. 16 -18 After completion of the experiment, ink was injected through the cannula, and the animals were perfused with saline followed by a solution of 4% formaldehyde and, finally, with a 30% sucrose solution. Sections of 40 /xm of the brainstem were stained with cresyl violet stain, and proper placement of the pipette tip in the area postrema, NTS, and Cl area was verified by the histological sections under the microscope.
The drugs were dissolved in sterile saline to the final concentrations in a volume not exceeding 60 nl. The following drugs were used: urethane (Aldrich, Milwaukee, Wisconsin), L-glutamic acid (NBC, Cleveland, Ohio), human NPY (Peninsula, Belmont, California), and peptide YY (Bachem Inc., Torrance, California). The NPY antiserum used in these experiments was raised in rabbits against porcine NPY and obtained from Amersham, Arlington Heights, Illinois. The antibody has been reported to show total cross-reactivity with NPY and no significant cross-reactivity with peptide YY (Amersham). It was injected as undiluted serum or at several dilutions as indicated in particular experiments. Undiluted NPY antiserum was heat-inactivated with a temperature of 100° C, and in preliminary experiments, when incubated in vitro with different concentrations of NPY, it failed to prevent cardiovascular effects of this peptide. In subsequent experiments, the inactivated antiserum was microinjected 10 minutes before similar intra-NTS administration of NPY. Control rabbit serum was purchased from Vector Labs, Burlingame, California).
For statistical analyses, Student's paired / test or analysis of variance followed by a Dunnett's test for significant differences was used as appropriate. Differences with a p<0.05 were taken as significant. All data are presented as mean±SEM.
Results
Unilateral microinjection of 4.65 pmol of NPY in the NTS produced a marked fall in BP and HR ( Figure 1A ). The effects were almost immediate and peaked about 30 seconds after administration of the peptide ( Figure 1A ). In most of the animals, recovery of the hypotensive and bradycardic effect was completed after 10 and 20 minutes, respectively. No tachyphylaxis was observed after repeated administration of similar doses of NPY in the same site of the NTS under these experimental conditions (not shown). Different concentrations of NPY were then injected into the right NTS of several rats. A dose of 46.5 fmol did not affect BP or HR. Contrary to the results reported by Carter et al, 14 all the subsequent doses studied (465 fmol, 1.55 pmol, and 4.65 pmol) decreased systolic, diastolic, mean BP, heart rate ( Figure 2 ), and respiratory rate (decreased from 79±2 to 28±3 breaths/min after 4.65 pmol, n=6). No pressor effect was noted even with the smallest dose ( Figure 2) . In five animals, we studied the effects of bilateral administration of NPY in the NTS. A total dose of 9.3 pmol of this peptide into the right and left NTS decreased BP by -48±4 mm Hg and HR by 181 ±17 beats/min. The effect was much more prolonged, and respiratory arrest was a prom- inent feature that required artificial ventilation to avoid further depression of cardiovascular function.
The area postrema might participate in the cardiovascular effects of some peptides such as angiotensin II 1920 and opioids. 21 No previous studies have attempted to investigate the cardiovascular effects of NPY in this area. Microinjection of NPY into the area postrema produced an initial pressor and tachycardic effect, followed by gradual hypotension and bradycardia ( Figure IB) of -15±2 mm Hg and heart rate of -14±4 beats/ min (see Figure IB and Table 1 ). The hypotension and bradycardia produced by this peptide in the area postrema were distinctly less prominent than those in the NTS (see Table 1 and Figure 2) .
The Cl area of the ventrolateral medulla has important connections with the NTS. 22 Unilateral microinjection of NPY in the Cl area produced a dose-related, long-lasting increase in BP with a rapid decrease in HR, which returned rapidly to basal levels ( Figures 1C and 3) . No effects on respiratory rate were observed.
To determine the specificity of the cardiovascular effects of exogenously administered NPY, we used a selective NPY antiserum. The injection of this antiserum (in a 1:10 dilution) into the NTS almost completely abolished the effects of subsequent injections of NPY into the NTS (Figures 4A and 5) . Further dilution of the antiserum was less effective in inhibiting NPY effects (not shown). The effects of the antiserum were selective on NPY, because the antibody did not inhibit the cardiovascular effects of L-glutamate in the NTS; furthermore, heatinactivated NPY antiserum did not antagonize the hypotensive and bradycardic effect of NPY in this place ( Figure 4B ). The injection of the intact antiserum into the NTS itself caused a small depressor (-5± 1 mm Hg) and bradycardic (-15±2 beats/min) effect ( Figure 4A ). However, this effect is probably nonspecific, because heat-inactivated antiserum also has similar effects (-6± 1 mm Hg and -13±2 beats/ min, n=3). In control studies, normal rabbit serum Neuropeptide Y (4.65 pmol) was injected in 60 nl over 10 seconds. SEM from seven experiments are shown.
•Significantly different from control values. Mean blood pressure (MBP) and heart rate (HR) response are given in change from basal values listed above. had no effect on the subsequent injections of NPY into the NTS (not shown).
Additionally, we also investigated if the cardiovascular effects of a very closely related NPY substance, peptide YY, were similarly inhibited by the NPY antiserum in the NTS. When compared with NPY, equimolar administration (4.65 pmol) of peptide YY into the NTS elicited only a modest and very brief decrease in BP (-12±2 mm Hg) and HR (-40±12 beats/min, see respective values for NPY in Figure 5 ), which revolved within 3 minutes. Not even a 100 -fold greater concentration of peptide YY (465 pmol) into the NTS was able to elicit similar hypotension (-18±1 mm Hg) to 4.65 pmol of NPY (see Figure 5 ). More importantly, the NPY antiserum was not able to modify any of the cardiovascular effects of intra-NTS peptide YY administration (9. 23 This underscores the importance of studying the actions of peptides in specific brain nuclei. The NTS has the first synapse of the baroreflex, and activation of neuronal groups in this area increase parasympathetic and decrease sympathetic tone. 2425 This study demonstrates that microinjection of NPY into the NTS causes a dosedependent reduction of BP and HR. Under similar experimental conditions, another group reported a pressor effect with small doses of NPY.
14 Although the reason for this discrepancy is not clear, it is important to note that in our study the substances were administered in a volume not exceeding 60 nl. In contrast, Carter et al 14 used a total volume of 200 nl. The importance of controlling this variable has been noted by several studies. Talman and Reis 26 reported that intra-NTS administration of vehicle over 300 nl caused pressor or depressor effects. Similarly, Barraco et al 27 demonstrated that the same concentration of a substance (adenosine) in the NTS has different effects on BP and HR if the volume of the drug is different.
The site of administration within the NTS might offer a further explanation for these conflicting results. In Carter's paper, the cannula was located more rostrally and closer to the area postrema than in our study. Diffusion of a substance (microinjected in a relatively large volume) to other brain 14 showed a biphasic effect on BP after a single dose of noradrenaline into their reported NTS site. Indeed, we have preliminary results that indicate that a biphasic response to noradrenaline is more compatible with intra-area postrema administration rather than NTS injection. Nevertheless, it still remains to be seen if this is responsible for the NPY and noradrenaline results in Carter's paper.
The relevance of NPY in many physiological responses has been hampered by the absence of specific receptor antagonists. Another valid possibility for characterizing the effects of NPY is the use of selective antiserum that recognizes only the peptide under study. Prior administration of the antiserum inhibited the effects of subsequent administration of NPY, whereas inactivated antiserum was not able to prevent these effects. The fact that the antiserum did not inhibit the effects of Lglutamate, and more importantly those of peptide YY, further supports this notion. The size and chemical structure of NPY and peptide YY are very similar. Both have 36-amino acids and they differ in the sequence of a few amino acids. 31 However, there are marked differences with respect to the cardiovascular effects of these two peptides. First, the decrease in BP and HR elicited by peptide YY are relatively modest. Second, the recovery from peptide YY effects are faster than for NPY (within 3 minutes). Finally, the NPY antiserum is not able to antagonize the effects of peptide YY. Furthermore, not all the substances microinjected into the NTS elicit cardiovascular responses. We have not been able to demonstrate changes in BP or HR after administration of the 28-amino acid peptide atrial natriuretic factor (authors' unpublished observation). Similarly, Casto and Phillips 32 demonstrated no change in cardiovascular activity after the administration into the NTS of several peptides, including somatostatin, bradykinin, and vasoactive intestinal peptide.
In the NTS the microinjection of the antiserum did not increase BP or HR. This might indicate absence of tonic release of NPY in the NTS. The observation that the antiserum slightly decreased hemodynamic parameters is probably a non-NPYspecific related effect, as the inactivated antiserum also elicited similar effects.
The depressor effect of NPY in the NTS is particularly striking; it is significantly greater than the effects reported in this site for other neuromodulators such as norepinephrine (-23 mm Hg with 23 nmol), 28 acetylcholine (-33 mm Hg with 440 pmol), 33 L-glutamate (-37 mm Hg with 6.8 nmol), 15 adeno-sine (-17 mm Hg with 2.3 nmol), 34 and /3-endorphin (-15 mm Hg with 280 fmol). 35 NPY has different effects in the area postrema and Cl area when compared with the NTS. A biphasic effect of NPY in BP and HR in the area postrema was observed, whereas pressor and bradycardic effect was noted in the Cl area. These results reflect the complexity of the cardiovascular effects of this polypeptide. The fact that i.e. administration of NPY causes a marked hypotensive response may be consistent with activation of neuronal pathways in the NTS and/or area postrema. It is unlikely that the i.e. effects of NPY are mediated by activation or inhibition of neuronal pathways in the Cl area in view that NPY increases BP but decreases HR in this neuronal group.
Although we have demonstrated the basic characteristics of the cardiovascular response to NPY in these three brainstem nuclei, little is known of the physiological role of NPY in each of these places. Different physiopathological states, anesthetics, or other factors may affect the response and interaction of NPY-mediated actions in NTS, area postrema, and Cl area. We are presently studying some of these possibilities.
In summary, our results demonstrate that exogenously applied NPY has distinct cardiovascular effects in the NTS, area postrema, and Cl area of the brainstem of the urethane-anesthetized rat, and they support a physiological role of NPY in the central nervous system.
